Glycemic control in children with type 1 diabetes treated with the advanced hybrid closed loop system 2-year prospective, observational, two-center study.

Background and Aims: MiniMed 780G is the first Advanced Hybrid Closed Loop (AHCL) system in Poland, approved in the EU in 2020. To date, observations of glycemic control up to 12 months have been published. This study aimed to analyze glycemic control and anthropometric parameters in children and adolescents with type 1 diabetes (T1D) after two years of using the AHCL system.
Materials and Methods: We prospectively collected anthropometric data, pump, and continuous glucose records of fifty T1D children (9.9 ± 2.4 years, 24 (48%) boys, T1D for 3.9 ± 2.56 years) using an AHCL system. We compared the two-week AHCL records obtained after AHCL enrollment with data 6, 12, and 24 months after starting AHCL.
Results: Time in range (70-180 mg/dl) and BMI z-score did not change during the 2 years of observation (p>0.05). The percentage of autocorrection in total daily insulin increased significantly (p<0.005).
Conclusion: Glycemic control in the investigated group of children with T1D treated with the AHCL system for 2 years remained stable. Children in this group maintained weight and optimal metabolic control, most likely due to autocorrection boluses.
Competing Interests: PJ-C has received speaker honoraria from Medtronic, Dexcom, Abbott, Ypsomed, and Roche, was a member of the advisory boards for Medtronic and Abbott, and received research support from Medtronic. SS has received speaker honoraria from Medtronic and Ypsomed. The remaining authors declare that the research was conducted without commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2024 Seget, Chobot, Tarasiewicz, Bielawska, Rusak, Ochab, Polanska and Jarosz-Chobot.)